Dutch biotechnology company Prosensa and multinational pharmaceutical company GlaxoSmithKline are moving ahead with plans to test drugs targeting several exons in the dystrophin gene

posted on October 29, 2012 - 5:00am
Update (Feb. 1, 2013): Dutch biopharmaceutical company Prosensa announced Jan. 29 that it has received orphan drug status in the United States and the European Union for compounds in development for the treatment of Duchenne muscular dystrophy.

New content is being added every day. Please check back again.